Nephron
Original Paper
Effects of Human Alpha-1-Acid Glycoprotein on Aminonucleoside- Induced Minimal Change Nephrosis in RatsMuchitsch E.-M.a · Pichler L.a · Schwarz H.P.a · Ulrich W.baResearch Laboratories, Immuno AG, und bJakob-Erdheim-Institut für Pathologie und Klinische Bakteriologie, Krankenhaus der Stadt Wien-Lainz, Wien, Österreich
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: February 10, 1999
Issue release date: 1999
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 2
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Abstract
A minimal change nephrosis was induced in rats by a single intraperitoneal injection of puromycin aminonucleoside (100 mg/kg). This resulted in increased urine protein output, plasma creatinine, blood urine nitrogen, and relative kidney weight. Electronoptically, there was a retraction of the glomerular podocytic foot processes. When human α1-acid glycoprotein was injected at 600 mg/kg intravenously on experimental days 6, 7, 8, and 9 into these animals, urine protein output decreased significantly, and the number of podocytic foot processes increased significantly. α1-Acid glycoprotein is rich in sialic acid and largely negatively charged. Its therapeutic role in nephrosis, which is characterized by a loss of sialic acid and a loss of negative charge, thereby leading to a loss of permselectivity, is discussed.
Related Articles:
References
- Haraldsson BS, Johnsson EKA, Rippe B: Glomerular permselectivity is dependent on adequate serum concentrations of orosomucoid. Kid Int 1992;41:310–316.
- Johnsson E, Haraldsson B: Addition of purified orosomucoid preserves the glomerular permeability for albumin in isolated perfused rat kidneys. Acta Physiol Scand 1993;147:1–8.
-
Schmid K: α1-Acid glycoprotein; in Putnam FW (ed): The Plasma Proteins: Structure, Function and Genetic Control, ed 2. New York, Academic Press, 1975, vol 1, pp 183– 228.
-
Frenk S, Antonowicz I, Craig JM, Metcoff J: Experimental nephrotic syndrome induced in rats by aminonucleoside: Renal lesions and body electrolyte composition. Proc Soc Exp Biol Med 1955;89:424–427.
- Blau EB, Michael AF: Rat glomerular glycoprotein composition and metabolism in aminonucleoside nephrosis. Proc Soc Exp Biol Med 1972;141:164–172.
- Olson JL, Rennke HG, Venkatachalam MA: Alterations in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats. Lab Invest 1981;44:271–279.
-
Muchitsch E-M, Teschner W, Linnau Y, Pichler L: In vivo effects of α1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin. Arch Intern Pharmacodyn 1996;331:313–321.
- Stonard MD, Gore CW, Oliver GJA, Smith IK: Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney. Fund Appl Toxicol 1987;9:339–351.
- Ryan GB, Karnovsky MJ: An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kid Int 1975;8:219–232.
- Kubosawa H, Kondo Y: Reevaluation of anionic sites in the rat glomerular basement membrane. Nephron 1997;76:445–451.
- Haraldsson B, Rippe B: Orosomucoid as one of the serum components contributing to normal capillary permselectivity in rat skeletal muscle. Acta Physiol Scand 1987;129:127–135.
- Curry FE, Rutledge JC, Lenz JF: Modulation of microvessel wall charge by plasma glycoprotein orosomucoid. Am J Physiol 1989;257:H1354–H1359.
- Childs WJ, Doak PB, Herdson PB: Lipoid nephrosis and focal glomerulosclerosis. Pathology 1978;10:113–129.
- Vernier RL, Klein DJ, Sisson SP, Mahan JD, Oegema TR, Brown DM: Heparan sulfate-rich anionic sites in the human glomerular basement membrane: Decreased concentration in congenital nephrotic syndrome. N Engl J Med 1983;309:1001–1009.
Article / Publication Details
Published online: February 10, 1999
Issue release date: 1999
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 2
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
